Product category:
Contract research
News Release from: Pharmaceutical Profiles | Subject: Webinar
Edited by the Laboratorytalk Editorial
Team on 30 May 2003
Human absorption studies webcast
The role of absorption studies in humans is to be examined by one of the pharmaceutical industry's leading authorities in oral drug delivery in a web-based seminar
The role of absorption studies in humans is to be examined by one of the pharmaceutical industry's leading authorities in oral drug delivery in the first in a series of webinars (web-based seminars) The on-line sessions have been designed by Pharmaceutical Profiles to address some of the key challenges facing all companies developing pharmaceutical products
This article was originally published on Laboratorytalk on 3 Jun 2003 at 8.00am (UK)
Related stories
Added value for pharmacokinetic studies
Service designed to maximise the data obtained from 'standard' clinical studies in healthy volunteers has been launched by an early phase drug development specialist
Human microdosing points the way forward
A microdose is 100 times below the level calculated to yield a pharmacological effect or 100 micrograms, whichever is the lower
The first webinar on 4 June 2003 at 4.00pm UK/5.00pm central Europe/11.00am eastern USA/8.00am Pacific USA will be delivered by Professor Ian Wilding - a frequent speaker at international meetings and a respected authority on drug delivery and intestinal absorption.
In 1997, he served as an expert scientist for the FDA in the area of Food Effects on Drug Bioavailability and is currently the only European scientist working with PQRI (an FDA/AAPS initiative) examining US regulatory guidance in the area of oral biopharmaceutics.
He is also on the advisory board for the University of Nottingham Institute of Enterprise and Innovation and is a member of the steering committee for the East Midlands MediLink programme, designed to improve connectivity between universities, hospitals, SMEs and large companies within the healthcare discipline in the region.
Further reading
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
Professor Wilding explained; "Pharmacokinetic (PK) or bioavailability issues have to be taken into account when drugs are selected as full development candidates.
However, the difficulty still exists to screen for human PK properties.
"The correlation between pre-clinical animal models and man is far from convincing.
However, one of the main reasons for the prediction dilemma has been the limited understanding of what controls human drug absorption.
New techniques for assessing which factors influence oral drug absorption in different regions of the gastrointestinal tract have gone some way in addressing this.
"Pharmaceutical and drug delivery companies are undertaking human drug absorption studies to create more reliable 'route maps' for developing new drugs with complex PK properties.
Such studies are ideal for generating radical innovations in development by providing mechanisms to make informed decisions about the likely chance of bioavailability success for a candidate drug through optimised formulation development.
That is the process this webinar will examine." Anyone wishing to participate in the webinar can register through the Pharmaceutical Profiles website following the link to 'news'.
• Pharmaceutical Profiles: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
